product
guidelin
involv
follow
step
establish
work
group
compris
expert
field
virolog
hsct
follow
literatur
review
februari
medlin
search
systemat
public
english
use
follow
key
word
respiratori
viral
infect
stem
cell
transplant
chemotherapi
human
rhinoviru
hrv
human
metapneumoviru
hmpv
respiratori
syncyti
viru
rsv
human
parainfluenza
hpiv
influenza
diagnosi
prevent
treatment
report
major
confer
includ
american
societi
haematolog
european
bone
marrow
transplant
annual
meet
also
review
februari
use
keywordsdevelop
key
recommend
base
random
control
trial
evid
due
pauciti
random
studi
recommend
base
literatur
review
consensu
expert
opinionth
grade
nomenclatur
use
evalu
level
evid
assess
strength
recommend
grade
criteria
specifi
bcsh
guidelin
pack
grade
work
group
websit
inform
avail
follow
websit
review
bcsh
committe
bsbmt
execut
committe
uk
clinic
virolog
network
uk
paediatr
bone
marrow
transplant
groupreview
sound
board
british
societi
haematolog
bsh
allogen
transplant
centr
uk
strong
grade
strong
recommend
grade
made
confid
benefit
outweigh
harm
burden
grade
recommend
appli
uniformli
patient
regard
recommend
weak
grade
magnitud
benefit
less
certain
weaker
grade
recommend
made
grade
recommend
requir
judici
applic
individu
patient
regard
suggest
qualiti
evid
grade
high
moder
b
low
c
put
context
use
consid
uncertainti
knowledg
whether
research
could
chang
know
certainti
high
research
unlik
chang
confid
estim
effect
current
evid
deriv
random
clinic
trial
without
import
limit
b
moder
research
may
well
import
impact
confid
estim
effect
may
chang
estim
current
evid
deriv
random
clinic
trial
import
limit
eg
inconsist
result
imprecis
wide
confid
interv
methodolog
flaw
eg
lack
blind
larg
loss
failur
adher
intent
treat
analysi
strong
evid
observ
studi
case
seri
eg
larg
larg
consist
estim
magnitud
treatment
effect
demonstr
gradient
c
low
research
like
import
impact
confid
estim
effect
like
chang
estim
current
evid
observ
studi
case
seri
opinion
respiratori
viral
infect
common
gener
popul
pose
particular
threat
patient
haematolog
malign
undergo
hsct
incid
infect
respiratori
virus
patient
undergo
haematolog
malign
hsct
like
reflect
incid
commun
whimbey
et
al
common
respiratori
virus
respect
serotyp
season
variat
incub
period
mode
transmiss
detail
tabl
public
health
england
nation
infect
servic
http
recommend
diagnosi
respiratori
viral
infect
made
polymeras
chain
reaction
pcr
test
recommend
diagnosi
upper
respiratori
tract
infect
made
upper
respiratori
tract
specimen
obtain
nasopharyng
aspir
wash
collect
nasal
throat
swab
recommend
diagnosi
lower
respiratori
tract
infect
made
lower
respiratori
tract
specimen
eg
bronchoalveolar
lavag
tracheal
aspir
induc
sputum
possibl
recommend
patient
assess
risk
factor
progress
lower
respiratori
tract
infect
increas
mortal
prior
decid
treatment
plan
vaccin
current
avail
rsv
hpiv
hrv
hmpv
infect
patient
household
contact
staff
encourag
receiv
influenza
vaccin
annual
basi
accord
nation
guidanc
green
book
public
health
england
prophylaxi
may
option
immunosuppress
individu
close
contact
proven
influenza
ill
expos
person
effect
cover
vaccin
nation
institut
health
care
excel
nice
becom
immunosuppress
result
either
underli
diseas
condit
abl
treatment
use
hsct
post
exposur
prophylaxi
could
help
patient
receiv
vaccin
addit
could
help
situat
vaccin
administ
provid
protect
circul
strain
viru
patient
recent
receiv
rituximab
may
also
respond
vaccin
berglund
et
al
recommend
prophylaxi
updat
annual
avail
public
health
england
suggest
websit
review
directli
ensur
guidanc
date
http
wwwgovukgovernmentcollectionsseasonalinfluenzaguidancedataandanalysi
last
access
novemb
recommend
provid
health
protect
scotland
base
recommend
http
wwwhpsscotnhsukrespseasonalinfluenzaaspx
last
access
novemb
public
health
wale
also
follow
similar
recommend
http
last
access
juli
current
recommend
mg
oseltamivir
oral
daili
domin
influenza
strain
lower
risk
oseltamivir
resist
eg
recommend
provid
lower
dose
children
year
age
ideal
therapi
start
within
h
exposur
advic
specialist
inhal
zanamivir
mg
daili
adult
children
year
age
licens
children
year
altern
domin
influenza
strain
like
resist
oseltamivir
eg
ideal
therapi
start
within
h
last
contact
use
zanamivir
reli
abil
adult
child
effect
use
inhal
intraven
nebul
zanamivir
unlicens
avail
compassion
use
name
patient
basi
tabl
highlight
infect
control
measur
set
patient
haematolog
malign
diagnos
suspect
respiratori
viru
infect
isol
singl
room
neutral
air
pressur
ideal
antechamb
particularli
import
patient
influenza
infect
receiv
treatment
ribavirin
accommod
room
posit
pressur
infect
control
measur
remain
place
patient
longer
symptom
acut
respiratori
viru
infect
test
neg
respiratori
viru
discuss
specialist
clinic
virolog
microbiolog
infecti
diseas
healthcar
worker
urti
lrti
symptom
avoid
contact
suscept
patient
possibl
appreci
might
alway
practic
hirsch
et
al
treatment
unit
measur
place
stop
spread
infect
may
mean
cohort
patient
screen
patient
event
outbreak
insuffici
evid
support
routin
screen
although
may
help
event
outbreak
respiratori
viral
infect
easili
transmit
person
person
patient
haematolog
malign
advis
avoid
contact
patient
respiratori
viral
infect
commun
possibl
hirsch
et
al
urti
lrti
symptom
isol
patient
clinic
ambulatori
care
facil
possibl
hirsch
et
al
recommend
patient
undergo
treatment
haematolog
malign
haematopoiet
stem
cell
transplant
well
staff
care
household
contact
receiv
influenza
vaccin
annual
basi
recommend
current
public
health
england
recommend
post
exposur
prophylaxi
influenza
infect
follow
recommend
allogen
transplant
patient
undergo
treatment
haematolog
malign
respiratori
tract
symptom
isol
patient
set
possibl
suggest
screen
patient
may
consid
event
outbreak
respiratori
viral
infect
recommend
allogen
transplant
patient
undergo
treatment
haematolog
malign
respiratori
viral
infect
isol
side
room
neutral
air
pressur
antechamb
undergo
treatment
recommend
patient
respiratori
virus
activ
screen
includ
pneumocysti
jirovecii
recommend
patient
respiratori
virus
monitor
sign
respiratori
failur
critic
care
team
involv
requir
recommend
immunosuppress
reduc
possibl
patient
respiratori
virus
recommend
patient
symptom
suggest
upper
lower
respiratori
tract
infect
screen
respiratori
viral
infect
prior
commenc
therapi
recommend
consider
given
delay
cytotox
therapi
haematopoiet
stem
cell
transplant
patient
activ
respiratori
viral
infect
favipiravir
toyama
chemic
investig
antivir
drug
function
nucleotid
analogu
inhibitor
viral
rna
polymeras
furuta
et
al
shown
effect
season
vitro
sleeman
et
al
recommend
current
public
health
england
guidanc
follow
manag
influenza
infect
ribavirin
known
effect
rna
virus
includ
rsv
drug
avail
aerosol
intraven
oral
use
time
write
access
aerosol
ribavirin
uk
limit
licens
product
longer
avail
altern
aerosol
product
manufactur
valeant
pharmaceut
quebec
canada
may
avail
centr
uk
unlicens
would
need
import
toxic
associ
administr
aerosol
ribavirin
includ
bronchospasm
cough
claustrophobia
nausea
rash
reduc
pulmonari
function
mucu
plug
conjunctiv
irrit
shah
chemali
potenti
risk
ribavirin
teratogen
mutagen
patient
staff
made
awar
risk
document
full
summari
product
characterist
http
last
access
april
intraven
ribavirin
associ
haemolysi
leucopenia
hyperbilirubinaemia
oral
ribavirin
associ
anaemia
nausea
shah
chemali
full
toxic
profil
oral
ribavirin
avail
summari
product
characterist
http
last
access
decemb
recent
adult
studi
compar
use
intermitt
versu
continu
aerosol
ribavirin
administr
found
statist
differ
progress
lrti
durat
viral
shed
two
regimen
chemali
et
al
avail
data
efficaci
aerosol
ribavirin
larg
limit
singl
centr
studi
boeckh
et
al
report
random
control
trial
aerosol
ribavirin
dose
g
time
daili
compar
support
care
patient
upper
respiratori
tract
rsv
infect
patient
includ
children
includ
due
slow
accrual
period
end
point
develop
clinic
pneumonia
occur
ribavirin
recipi
control
patient
patient
aliv
boeckh
et
al
recent
detail
review
shah
chemali
includ
random
control
trial
plu
prospect
studi
retrospect
studi
hsct
patient
receiv
aerosol
ribavirin
without
intraven
immunoglobulin
ivig
signific
reduct
progress
lrti
receiv
ribavirin
urti
stage
compar
compar
p
median
durat
therapi
vari
studi
usual
although
longer
sever
infect
shah
chemali
conclus
review
articl
reflect
recent
studi
adult
paediatr
allogen
transplant
patient
also
found
aerosol
ribavirin
urti
stage
import
singl
factor
reduc
progress
lrti
mortal
shah
et
al
retrospect
studi
review
outcom
patient
rsv
infect
januari
may
patient
treat
aerosol
ribavirin
andor
ivig
discret
treat
physician
group
subsequ
publish
immunodefici
score
index
base
data
patient
studi
present
urti
symptom
shah
et
al
patient
stratifi
low
medium
group
base
score
system
see
tabl
patient
score
classifi
score
classifi
moder
risk
score
classifi
shah
et
al
patient
significantli
risk
lrti
mortal
moder
patient
p
patient
group
also
greatest
benefit
ribavirin
administ
urti
stage
score
system
yet
valid
prospect
cohort
patient
view
recent
lack
avail
aerosol
ribavirin
consider
interest
use
oral
ribavirin
rsv
infect
hsct
recipi
oral
ribavirin
licens
treatment
respiratori
virus
use
sever
report
khanna
et
al
report
retrospect
review
adult
patient
rsv
urti
lrti
patient
undergon
allogen
hsct
patient
receiv
treatment
oral
ribavirin
ivig
oral
ribavirin
plu
palivizumab
urti
lrti
oral
ribavirin
administ
load
dose
mgkg
increas
mg
three
time
daili
day
mg
three
time
daili
day
four
patient
requir
mechan
ventil
receiv
iv
ribavirin
use
dose
regimen
mortal
five
patient
develop
haemolysi
khanna
et
al
recent
studi
use
oral
ribavirin
adult
patient
rsv
infect
casey
et
al
seven
patient
urti
lrti
patient
receiv
oral
ribavirin
dose
mgkgd
four
divid
dose
escal
depend
clinic
respons
total
dose
mgkgd
along
ivig
three
patient
die
respiratori
infect
seven
patient
urti
progress
lrti
start
dose
mgkgd
six
subsequ
respond
higher
dose
median
durat
therapi
rang
patient
develop
haemolysi
marcelin
et
al
also
recent
report
use
oral
ribavirin
heterogen
patient
group
patient
includ
hsct
recipi
patient
die
rsv
infect
one
develop
haemolyt
anaemia
lactic
acidosi
anoth
develop
alter
mental
statu
marcelin
et
al
although
evid
limit
oral
ribavirin
appear
safe
treatment
urti
hsct
recipi
start
dose
higher
mgkgd
eg
mgkgd
may
effect
casey
et
al
intraven
ribavirin
licens
treatment
respiratori
virus
also
use
sever
small
seri
shah
chemali
report
review
four
retrospect
studi
two
prospect
studi
use
oral
intraven
ribavirin
without
ivig
adult
patient
receiv
treatment
lrti
die
shah
chemali
limit
data
avail
patient
receiv
intraven
ribavirin
urti
stage
suggest
use
intraven
ribavirin
restrict
patient
requir
therapi
unabl
receiv
oral
aerosol
ribavirin
intraven
ribavirin
may
help
patient
receiv
mechan
ventil
limit
evid
efficaci
treatment
rsv
patient
undergo
autolog
transplant
chemotherapi
treatment
anaissi
et
al
report
adult
undergo
chemotherapi
without
autolog
transplant
patient
screen
larg
number
patient
patient
found
rsv
posit
patient
receiv
treatment
signific
increas
seriou
respiratori
complic
patient
rsv
suggest
patient
undergo
chemotherapi
treatment
autolog
transplant
would
gener
requir
rsv
specif
therapi
decis
made
basi
recommend
aerosol
ribavirin
administ
allogen
transplant
patient
lower
respiratori
tract
infect
respiratori
syncyti
viru
oral
ribavirin
may
altern
allogen
transplant
patient
lower
respiratori
tract
infect
rsv
aerosol
ribavirin
avail
recommend
intraven
immunoglobulin
administ
allogen
transplant
patient
respiratori
syncyti
viru
infect
recommend
aerosolizedor
ribavirin
administ
allogen
transplant
patient
upper
respiratori
tract
infect
respiratori
syncyti
viru
multipl
risk
factor
progress
lower
respiratori
tract
infect
patient
hmpv
requir
therapi
although
prolong
asymptomat
shed
may
occur
may
infect
control
issu
requir
confirm
neg
viral
pcr
discuss
clinic
virolog
prior
relax
infect
control
measur
urti
treat
evid
reduc
risk
lrti
occurr
lrti
assess
basi
immunodefici
score
index
shah
et
al
may
use
howev
must
appreci
lrti
hmpv
adult
compar
rsv
influenza
associ
similar
complic
rate
includ
intens
care
unit
icu
admiss
mechan
ventil
length
hospit
length
stay
icu
widmer
et
al
jain
et
al
high
preval
previou
infect
popul
mean
rel
high
titr
hmpv
neutral
antibodi
found
pool
ivig
vitro
studi
shown
similar
efficaci
ivig
rsv
hmpv
wyde
et
al
ivig
dose
gkg
weekli
use
sever
case
studi
small
seri
treat
patient
hmpv
et
al
kitanovski
et
al
publish
studi
use
ribavirin
treat
hmpv
somewhat
inconclus
ribavirin
valid
treatment
option
select
case
sever
case
studi
report
resolut
infect
patient
advanc
lrti
use
intraven
safdar
bonney
et
al
oral
egli
et
al
nebul
ribavirin
shahda
et
al
renaud
et
al
usual
combin
ivig
recent
seattl
group
publish
experi
treat
lrti
caus
hmpv
n
compar
outcom
rsv
lrti
n
mortal
similar
renaud
et
al
impact
outcom
use
nebul
ribavirin
ivig
import
limit
studi
addit
small
retrospect
seri
studi
popul
imbalanc
half
hmpv
patient
receiv
ivig
ribavirin
delay
time
start
ribavirin
treatment
group
patient
receiv
therapi
advanc
diseas
present
earlier
untreat
group
human
monoclon
antibodi
target
hmpv
fusion
show
promis
ulbrandt
et
al
hamelin
et
al
corti
et
al
candid
peptid
antivir
also
develop
deffrasn
et
al
howev
present
none
approach
commerci
avail
current
effect
vaccin
avail
present
uncertainti
role
ribavirin
hmpv
routin
recommend
may
use
select
patient
discret
treat
physician
therapi
hpiv
infect
gener
support
togeth
respiratori
isol
given
corticosteroid
therapi
risk
factor
progress
lrti
reduct
steroid
dosag
appropri
feasibl
may
valid
approach
therapi
ison
proven
agent
exist
anecdot
report
suggest
role
ribavirin
whether
aerosol
oral
intraven
form
sparrelid
et
al
chakrabarti
et
al
dignan
et
al
stankova
et
al
shima
et
al
casey
et
al
howev
patient
diagnos
direct
fluoresc
antibodi
cultur
ribavirin
given
nebul
found
improv
viral
shed
surviv
regardless
concurr
use
immunoglobulin
absenc
ison
remain
uncertainti
use
ribavirin
hpiv
infect
may
consid
select
high
risk
patient
lrti
altern
antivir
agent
earli
phase
clinic
trial
develop
alymova
et
al
chen
et
al
barik
lu
vaccin
develop
sever
decad
number
live
attenu
vaccin
undergo
clinic
trial
unlik
directli
applic
immunosuppress
patient
may
prove
use
context
vaccin
household
contact
rubin
et
al
reduct
risk
initi
viral
infect
immunosuppress
may
reduc
risk
secondari
bacteria
fungal
infect
alymova
et
al
bosch
et
al
current
specif
treatment
avail
hrv
infect
agent
pleconaril
studi
patient
specif
set
hsct
limit
effect
reduct
symptom
durat
observ
drug
ultim
acquir
viral
resist
detect
hayden
et
al
pevear
et
al
anoth
drug
evalu
phase
ii
studi
enrol
inhal
similarli
investig
asthmat
neither
agent
yet
test
hsct
recipi
vaccin
hrv
remain
challeng
prospect
due
mainli
presenc
hrv
serotyp
recommend
support
care
use
manag
hrv
infect
due
insuffici
evid
support
specif
therapi
recent
studi
confirm
increas
mortal
patient
hrv
infect
underli
need
research
better
intervent
hrv
infect
campbel
et
al
recommend
support
care
use
manag
rhinoviru
insuffici
evid
support
specif
treatment
treatment
ribavirin
recommend
patient
upper
respiratori
tract
infect
parainfluenza
metapneumoviru
recommend
diagnosi
respiratori
viral
infect
made
polymeras
chain
reaction
pcr
test
diagnosi
upper
respiratori
tract
infect
made
upper
respiratori
tract
specimen
obtain
nasopharyng
aspir
wash
collect
nasal
throat
swab
diagnosi
lower
respiratori
tract
infect
made
lower
respiratori
tract
specimen
eg
bronchoalveolar
lavag
tracheal
aspir
induc
sputum
possibl
patient
assess
risk
factor
progress
lower
respiratori
tract
infect
prior
decid
treatment
plan
patient
undergo
treatment
haematolog
malign
haematopoiet
stem
cell
transplant
well
staff
care
household
contact
receiv
influenza
vaccin
annual
basi
current
public
health
england
recommend
post
exposur
prophylaxi
influenza
infect
follow
allogen
transplant
patient
undergo
treatment
haematolog
malign
respiratori
tract
symptom
isol
patient
set
possibl
suggest
screen
patient
may
consid
event
outbreak
respiratori
viral
infect
recommend
allogen
transplant
patient
undergo
treatment
haematolog
malign
respiratori
viral
infect
isol
side
room
neutral
air
pressur
antechamb
undergo
treatment
recommend
patient
respiratori
virus
activ
screen
includ
pneumocysti
jirovecii
patient
respiratori
virus
monitor
sign
respiratori
failur
critic
care
team
involv
requir
immunosuppress
reduc
possibl
patient
respiratori
virus
patient
upper
lower
respiratori
tract
symptom
screen
respiratori
viral
infect
prior
commenc
therapi
consider
given
delay
cytotox
therapi
haematopoiet
stem
cell
transplant
patient
activ
respiratori
viral
infect
current
public
health
england
guidanc
follow
manag
influenza
infect
aerosol
ribavirin
administ
allogen
transplant
patient
lower
respiratori
tract
infect
respiratori
syncyti
viru
oral
ribavirin
may
altern
allogen
transplant
patient
lower
respiratori
tract
infect
rsv
aerosol
ribavirin
avail
intraven
immunoglobulin
administ
allogen
transplant
patient
respiratori
syncyti
viru
infect
aerosolizedor
ribavirin
administ
allogen
transplant
patient
upper
respiratori
tract
infect
respiratori
syncyti
viru
multipl
risk
factor
progress
lower
respiratori
tract
infect
support
care
use
manag
rhinoviru
specif
treatment
treatment
ribavirin
recommend
patient
upper
respiratori
tract
infect
parainfluenza
metapneumoviru
advic
inform
guidelin
believ
true
accur
time
go
press
neither
author
british
societi
haematolog
british
societi
blood
marrow
transplant
uk
clinic
virolog
network
publish
accept
legal
respons
content
guidelin
none
declar
